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Abstract
Introduction: HIV-positive women have an increased risk of invasive cervical cancer but cytologic screening is effective in
reducing incidence. Little is known about cervical screening coverage or the prevalence of abnormal cytology among HIV-
positive women in Ukraine, which has the most severe HIV epidemic in Europe.
Methods: Poisson regression models were fitted to data from 1120 women enrolled at three sites of the Ukraine Cohort
Study of HIV-infected Childbearing Women to investigate factors associated with receiving cervical screening as part of HIV
care. All women had been diagnosed as HIV-positive before or during their most recent pregnancy. Prevalence of cervical
abnormalities (high/low grade squamous intraepithelial lesions) among women who had been screened was estimated, and
associated factors explored.
Results: Overall, 30% (337/1120) of women had received a cervical screening test as part of HIV care at study enrolment
(median 10 months postpartum), a third (115/334) of whom had been tested .12 months previously. In adjusted analyses,
women diagnosed as HIV-positive during (vs before) their most recent pregnancy were significantly less likely to have a
screening test reported, on adjusting for other potential risk factors (adjusted prevalence ratio (APR) 0.62, 95% CI 0.51–
0.75 p,0.01 for 1
st/2
nd trimester diagnosis and APR 0.42, 95% CI 0.28–0.63 p,0.01 for 3
rd trimester/intrapartum diagnosis).
Among those with a cervical screening result reported at any time (including follow-up), 21% (68/325) had a finding of
cervical abnormality. In adjusted analyses, Herpes simplex virus 2 seropositivity and a recent diagnosis of bacterial vaginosis
were associated with an increased risk of abnormal cervical cytology (APR 1.83 95% CI 1.07–3.11 and APR 3.49 95% CI 2.11–
5.76 respectively).
Conclusions: In this high risk population, cervical screening coverage as part of HIV care was low and could be improved by
an organised cervical screening programme for HIV-positive women. Bacterial vaginosis testing and treatment may reduce
vulnerability to cervical abnormalities.
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Introduction
Ukraine has the highest adult HIV prevalence in Europe,
estimated at 1.6% in 2007 [1]. Heterosexual transmission has now
overtaken injecting drug use (IDU) as the main mode of HIV
acquisition [2], and women account for almost half of those living
with HIV in Ukraine [3]. HIV-positive women are at increased
risk of acquisition and/or persistence or reactivation of cervical
infection with Human papillomavirus (HPV) [4–6]. This is due to
shared risk factors for acquisition (e.g. multiple sexual partners)
and immunosuppression [7,8]. Cervical abnormalities in HIV-
positive women are more likely to be severe, aggressive and
resistant to treatment [9,10], and HIV-positive women have a 5 to
8-fold increased risk of invasive cervical cancer compared with the
general population [11,12].
Regular cytologic screening can effectively reduce the incidence
of invasive cervical cancer by up to 80% on a population level
[13,14]. A two to three year screening interval is recommended by
British and US guidelines for HIV negative women of childbearing
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HIV-positive women, given their increased risk of morbidity
[17,18]. Screening during pregnancy is not recommended by UK
guidelines [15] because invasive cervical cancer in pregnant
women is very uncommon, and treatment for less severe
abnormality must be deferred until after delivery [19]. However,
antenatal screening may be justified for HIV-positive women given
their increased cancer risk. Perinatal care can also be an
opportunity to engage marginalised women, who are unlikely to
attend for screening at another time, and those who have
previously defaulted on follow-up appointments for abnormalities
[15]. However, cytologic samples taken during pregnancy (and up
to 12 weeks postpartum) may be more difficult to interpret than
samples taken at other times [20].
In Ukraine, cervical screening is recommended six-monthly for
all women of childbearing age [21]. It is available free of charge at
public health clinics, but is predominantly opportunistic. National
policy includes a low-level recommendation (expert opinion) for
screening as part of antenatal care, but there are no figures on
coverage in this group or nationally [22]. World Health Survey
data suggest that coverage with at least three-yearly screening in
the general population is similar in Ukraine to many other
European countries [23]. However, it is unclear whether this is the
case among HIV positive women, who are more likely to be
socially excluded [1] and require more intensive surveillance. Age-
standardised mortality rates for cervical cancer are two-fold higher
in Eastern than in Western Europe (7.1 vs 3.4 per 100,000) [24]
and little is known about the prevalence of abnormal cervical
cytology among HIV-positive women living in Eastern Europe.
We aimed to explore coverage of cervical screening as part of
HIV care in a cohort of HIV-positive childbearing women in
Ukraine receiving care at HIV/AIDS Centres, and to identify
factors associated with an abnormal finding.
Methods
The Ukraine Cohort Study of HIV-infected Childbearing
Women (‘‘Women’s Cohort’’) is an ongoing study established in
December 2007. HIV-infected women who had recently given
birth (usually within the last 12 months) and were receiving care at
one of five participating regional HIV/AIDS Centres in Ukraine
(situated in Odessa, Donetsk, Kiev, Kriviy Rig and Mykolaiv) were
enrolled with informed consent [25]. This postnatal cohort is
nested within the European Collaborative Study (ECS), a birth
cohort study in which pregnant HIV-infected women in ten
European countries are enrolled, and their infants prospectively
followed according to a standard protocol [26]. The Ukraine ECS
has been enrolling women since 2000 [27] and around 80% of
women in the postnatal study were also in the ECS, allowing
linkage across the two studies (both collect coded anonymised data
with unique identifiers).
Maternal socio-demographic information was collected as part
of the ECS (clinician-completed questionnaire) and at enrolment
in the Women’s Cohort (woman-completed questionnaire).
Clinical information, including data on cervical screening, was
provided by the clinician at enrolment and thereafter when a
woman returned to the HIV/AIDS Centre for care. Data
collection was opportunistic and dependent on routine clinic
visits; according to policy, clinic visits should be at least three
monthly for women on ART and six-monthly for those not on
treatment, but in practice follow-up intervals could be much
longer. All clinicians providing care at the HIV/AIDS Centres
were gynaecologists. Only information on screening tests received
as part of HIV care was available to them and reported in this
study.
Definitions
Results of cervical cytology were reported according to the 2001
Bethesda System as negative for intraepithelial lesion or
malignancy (‘normal’), low-grade squamous intraepithelial lesion
(LSIL) (corresponding to HPV infection, mild dysplasia or cervical
intraepithelial neoplasia (CIN) 1) and high-grade squamous
intraepithelial lesion (HSIL) (corresponding to moderate and
severe dysplasia, carcinoma in situ or CIN 2 and CIN 3) [28]. A
finding of LSIL or HSIL was defined as an abnormal result.
History of IDU was classified by self-report, clinical assessment
or abstinence syndrome in the neonate. HIV clinical status was
defined according to the World Health Organization (WHO)
clinical staging criteria (advanced and severe symptomatic HIV
disease corresponding to WHO stages 3 and 4 [29]). Previous
pregnancy was defined as a previous live birth, stillbirth,
miscarriage or termination, and multiparity as $1 previous live
or stillbirth. Age at enrolment was categorised approximately into
quartiles (16–23, 24–26, 27–30 and $31 years). Affordability of
contraception was based on self-report.
Genital infections diagnosed with the following methods during
the most recent pregnancy or postnatally (up to date of enrolment)
were reported: bacterial vaginosis (BV) by Gram stain microscopy
in 99% and by symptoms in 1%; vulvo-vaginal candida by Gram
stain microscopy in 77%, culture in 14% and symptoms in 10%;
Chlamydia Trachomatis (‘chlamydia’) by enzyme immunoassay on
endocervical swab; Trichomonas vaginalis (TV) by microscopy.
Data Analysis
Of the five centres participating in the study, analyses were
limited to Odessa, Kiev and Donetsk, as Kriviy Rig and Mykolaiv
did not report any cervical screening.
The x
2 and Fisher’s exact tests for categorical variables were
used to investigate univariable comparisons. Univariable and
multivariable Poisson regression models with a robust variance
estimate were fitted to estimate unadjusted and adjusted
prevalence ratios (PRs and APRs) of having a cervical screening
test reported at postnatal study enrolment, and of an abnormal
finding (LSIL or HSIL). The models for having a test reported
were fitted including all women and also restricted to those
diagnosed prior to conception of their most recent pregnancy. The
PRs and APRs thus estimated provide a more interpretable
measure of effect than those resulting from odds ratios obtained
with logistic regression models, which may be inflated where
outcomes are common, and control for under-dispersion and
confounding which depends on the measure of effect [30].
Explanatory variables investigated included socio-demographic
factors (age, parity, educational status), health behaviours (alcohol
use, smoking, IDU, contraceptive use, disclosure of HIV status),
clinical status (WHO stage, CD4 count), use of postnatal ART,
time since HIV diagnosis and self-reported affordability of
contraception and coinfection with viral hepatitis. Study centre
and year of enrolment (December 2007–08, 2009, 2010–11) were
included a priori in the multivariable analyses of factors associated
with having a test reported to account for differences in local
policy and changing clinical practice over time. Variables which
remained significantly associated with the outcome after these
adjustments (Wald test p,0.1) were included in the multivariable
models. In analyses of factors associated with an abnormal finding,
all variables known to be associated with invasive cervical cancer
and available in our dataset were included a priori in the models
(use of oral hormonal contraception, smoking, parity, Herpes
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Test reported at enrolment (n=337) No test at enrolment (n=783)
Median age at enrolment (IQR) 28.0
(25.2, 31.3)
27.0
(23.7, 30.2)
Marital status (n=1113)
Married 225 (67%) 412 (53%)
Cohabiting 73 (22%) 235 (30%)
Single
{/widowed/divorced 38 (11%) 130 (17%)
Previous pregnancies
{ (n=903)
1 95 (32%) 287 (47%)
2 87 (29%) 147 (24%)
3 or more 116 (39%) 171 (28%)
Age at leaving full-time education (n=653)
#16 years 32 (14%) 71 (16%)
17–18 years 44 (20%) 84 (19%)
$19 years 146 (66%) 276 (64%)
History of injecting drug use (n=1120)
No 247 (73%) 616 (79%)
Yes 90 (27%) 167 (21%)
Alcohol use postnatally (n=1104)
No 268 (81%) 603 (78%)
Yes 63 (19%) 170 (22%)
History of smoking (n=1114)
No 98 (29%) 238 (31%)
Yes 236 (71%) 542 (69%)
Current smoking (n=1111)
No 153 (46%) 389 (50%)
Yes 181 (54%) 388 (50%)
Disclosure of HIV status to anyone (n=1120)
No 15 (4%) 42 (5%)
Yes 322 (96%) 741 (95%)
Disclosure of HIV status to family/friends (n=1120)
No 107 (32%) 293 (37%)
Yes 230 (68%) 490 (63%)
Disclosure of HIV status to partner (n=1120)
No 67 (20%) 189 (24%)
Yes 270 (80%) 594 (76%)
WHO stage (n=1109)
1–2 255 (76%) 657 (85%)
3–4 82 (24%) 115 (15%)
CD4 count (n=959)
# 200 cells/mm
3 22 (7%) 63 (10%)
201–350 cells/mm
3 56 (18%) 114 (18%)
. 350 cells/mm
3 234 (75%) 470 (73%)
Median 468 cells/mm
3 456 cells/mm
3
Taking ART postnatally (n=1114)
No 262 (78%) 643 (82%)
Yes 72 (22%) 137 (18%)
Any OC
{ use reported postnatally (n=1120)
No 291 (86%) 715 (91%)
Yes 46 (14%) 68 (9%)
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count) [31]. Other variables were considered for inclusion in the
multivariable model only if significant in univariable analyses
(p,0.10).
Sexually transmitted infections (STIs) and genital infections
(vulvo-vaginal candida and BV) were not considered in the
analyses of factors associated with having a cervical screening test
reported due to problems with interpretation of potential
associations, particularly in terms of direction of effect, e.g.
cervical screening could have prompted investigation for infections
and vice versa. However, associations between STIs/genital
infections and cervical abnormality were explored as some
infections are known risk factors for invasive cervical cancer.
At the time of analysis, only 21% (233/1120) of women had
follow-up data available reflecting the recent establishment of this
cohort, long follow-up intervals among women not receiving ART,
and also possible loss to follow-up. As women with follow-up were
not representative of the cohort as a whole with respect to health-
seeking behaviours, follow-up data were omitted from analyses.
Data were managed in an Access 2003 database (Microsoft
Corps, Redmond, WA, USA) and statistical analyses were
performed in Stata version 11.0 (StataCorp LP, College Station,
Texas, USA).
Results
A total of 1120 women were enrolled at Odessa, Kiev and
Donetsk centres from December 2007 to March 2011, at a median
of 10 months postpartum (83% (924/1120) at $12 weeks
postpartum). Median age at enrolment was 27.3 years (IQR
24.2, 30.6). HIV diagnosis occurred a median of 1.5 years (IQR
1.0, 2.5) prior to enrolment. For two-thirds (665/971), this was
during their most recent pregnancy and for one third (306/971)
prior to conception. Women diagnosed ,6 months before
enrolment (and therefore within the interval for cervical screening
according to Ukraine policy) accounted for 7% (69/970).
Almost all (971/972) women were born in Ukraine and 23%
(257/1120) had a history of IDU, about a third (89/255) of whom
had a sex partner who also injected drugs. Of those without an
IDU history, 12% (88/716) reported a sex partner who injected
drugs. Overall a third (299/872) were seropositive for hepatitis C
virus (HCV), 55% (163/299) of whom had an IDU history. A
quarter (279/1111) did not know the HIV status of their partner,
39% (434/1111) were in a concordant partnership, 29% (317/
1111) in a discordant partnership and 7% (81/1111) had no
current partner. Of the 76% (851/1120) of women tested for
chlamydia, 25% (215/851) were positive, of whom 78% (164/211)
had at least one STI in addition to chlamydia and HIV (mostly
HSV-2). Overall, 18% (197/1109) had advanced or severe
symptomatic HIV disease (WHO stages 3 or 4), and 27% (255/
959) had a CD4 count #350 cells/mm
3. Almost half (44%, 422/
949) were multiparous at enrolment. Of those who reported being
sexually active postnatally, 88% (699/794) reported use of
condoms, most (83%, 581/699) as their only method of
contraception.
Cohort characteristics by cervical screening test receipt are
shown in Table 1, and prevalence of coinfections diagnosed during
pregnancy or postnatally in Table 2. Just under a third of women
(337/1120) had a cervical screening test reported at enrolment.
Over half of those with date of cervical screening test reported
(180/310) had received their most recent test postnatally (median
28 weeks after delivery, 17% (30/180) ,12 weeks after delivery),
24% (74/310) during pregnancy and 18% (56/310) pre-concep-
tion. Most (69%, 232/334) had been tested over six months and
34% (115/334) over one year previously (median 40 weeks prior to
enrolment). Women diagnosed with HIV prior to conception were
more likely than those diagnosed antenatally or intrapartum to
have a screening test reported at enrolment (44% (136/306) versus
26% (176/665), x
2=31.06 p,0.01). Of the 783 women with no
test at baseline, 22% (n=176) had follow-up data available, of
whom 39% (68/176) had been screened at follow-up.
Factors Associated with Having a Cervical Screening Test
Result Reported as Part of HIV Care
There was no significant change over time in the proportion of
women with a screening test reported as part of HIV care at study
enrolment (30% overall, p=0.87). In univariable analyses, age,
marital status, number of previous pregnancies, IDU history,
WHO clinical stage, timing of HIV diagnosis, affordability of
contraception and centre were significantly associated with having
a screening test at the HIV/AIDS Centre (Table 3). HCV
seropositivity and IDU history were both associated with report of
a screening test in univariable analysis (x
2=9.69, p,0.01 and
x
2=3.85, p=0.05 respectively), but not on adjusting for year and
centre (p=0.44 and p=0.48 respectively), and were therefore
excluded from the multivariable model. HCV seropositivity is
omitted from Table 3 due to its overlap with IDU history. Other
factors that were not associated with having a test reported were
smoking (current or history), current alcohol use, disclosure of
HIV status to a partner, postnatal ART receipt and CD4 count.
In the multivariable model, there were significant differences in
reporting of cervical screening tests by centre (Wald test p,0.01)
(Table 3), and women were twice as likely to have a test reported if
diagnosed prior to their most recent pregnancy rather during the
3
rd trimester or intrapartum. Women with one previous pregnancy
(vs $2) were less likely to have a test reported (p=0.05).
In order to investigate factors associated with being screened at
the HIV/AIDS Centre among women with longest exposure to
HIV care, a sub-analysis was conducted limited to the 306 women
diagnosed with HIV before their most recent pregnancy. In this
group, 44% (136/306) of whom had a cervical screening test result
reported at enrolment, age, marital status, self-reported afford-
ability of contraception, HIV disclosure and centre were
Table 1. Cont.
Test reported at enrolment (n=337) No test at enrolment (n=783)
Can afford family planning (self-report) (n=1089)
No 40 (12%) 179 (24%)
Yes 292 (88%) 578 (76%)
{Includes non-cohabiting partnerships;
{Previous pregnancies include still births, live births, miscarriages and terminations. OC, oral hormonal contraceptive.
doi:10.1371/journal.pone.0034706.t001
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Test reported at enrolment (n=337) No test at enrolment (n=783)
Chlamydia (n=851) 71 (25%) 144 (25%)
Syphilis (n=907) 13 (4%) 17 (3%)
Trichomonas vaginalis (n=645) 19 (6%) 52 (15%)
HSV-2 antibodies (n=806) 156 (55%) 255 (49%)
Vulvo-vaginal candida (n=739) 134 (43%) 232 (54%)
Bacterial vaginosis (n=731) 67 (22%) 59 (14%)
Hepatitis C seropositive (n=872) 120 (41%) 179 (31%)
Hepatitis B surface antigen positive (n=1002) 23 (7%) 61 (9%)
doi:10.1371/journal.pone.0034706.t002
Table 3. Factors associated with having a cervical screening test reported at study enrolment.
Proportion (n) with
test reported at
enrolment
Crude PR (95% CI)
n=870
{ p-value
Adjusted PR – multivariable
model (95% CI) n=870 p-value
Age at enrolment
16–23 years 21% (55/265) 1.00 1.00
24–26 years 31% (78/255) 1.25 (0.91,1.73) 0.17 1.07 (0.78,1.47) 0.68
27–30 years 33% (111/339) 1.49 (1.11,2.00) ,0.01 1.13 (0.84,1.51) 0.42
$31 years 36% (92/257) 1.55 (1.14,2.10) ,0.01 1.24 (0.90,1.69) 0.18
Marital status
Married 35% (225/637) 1.00 1.00
Cohabiting 24% (73/308) 0.72 (0.56,0.92) ,0.01 0.81 (0.63,1.04) 0.10
Single/widowed/divorced 23% (38/168) 0.68 (0.50,0.93) 0.02 0.84 (0.61,1.16) 0.29
Previous pregnancies at enrolment
$2 39% (203/521) 1.00 1.00
1 25% (95/382) 0.64 (0.52,0.79) ,0.01 0.80 (0.65,1.00) 0.05
History of IDU
No 29% (247/863) 1.00
Yes 35% (90/257) 1.24 (1.01,1.52) 0.04
WHO clinical stage
1–2 28% (255/912) 1.00 1.00
3–4 42% (82/197) 1.37 (1.12,1.68) ,0.01 1.07 (0.87,1.32) 0.51
Timing of HIV diagnosis
Prior to conception 44% (136/306) 1.00 1.00
1
st/2
nd trimesters 28% (155/545) 0.60 (0.50,0.73) ,0.01 0.62 (0.51,0.75) ,0.01
3
rd trimester/intrapartum 18% (21/120) 0.41 (0.27,0.61) ,0.01 0.42 (0.28,0.63) ,0.01
Affordability of contraception
Can afford 34% (292/870) 1.00 1.00
Can’t afford 18% (40/219) 0.62 (0.45,0.85) ,0.01 0.76 (0.54,1.07) 0.12
Year of enrolment
2007/08 30% (101/339) 1.00 1.00
2009 31% (135/435) 1.05 (0.84,1.31) 0.67 0.96 (0.76,1.20) 0.71
2010/11 29% (101/344) 1.18 (0.93,1.50) 0.17 0.97 (0.76,1.23) 0.80
Centre of enrolment
Odessa 26% (111/419) 1.00 1.00
Kiev 39% (207/528) 1.26 (1.03,1.55) 0.03 1.32 (0.07,1.63) ,0.01
Donetsk 11% (19/173) 0.42 (0.25,0.71) ,0.01 0.49 (0.29,0.82) ,0.01
{Limited to 870 women included in the multivariable model.
doi:10.1371/journal.pone.0034706.t003
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analyses (Table 4). In the multivariable analyses adjusting for year,
centre and affordability of contraception, women leaving full-time
education at #16 (vs $19 years) and who were cohabiting (vs
married) were less likely to have a test reported, although the latter
was not statistically significant (p=0.06) (Table 4). The four-
category age variable did not significantly contribute to fit of the
model when adjusting for year and centre (Wald test p=0.14),
however women $27 years were significantly more likely to have a
test reported than those ,27 years when a binary variable was
used (APR 1.57, 95% CI 1.11–2.20 adjusting for marital status,
education, affordability of contraception, year and centre,
p=0.01).
Although not considered in Poisson regression analyses for
reasons specified in the methods, BV was more common among
women with a cervical screening test result reported than among
those without (22% (67/311) vs 14% (59/420) respectively,
x
2=7.04, p,0.01). Women with a cervical screening test reported
were also more likely to have been tested for BV (92%, 311/337 vs
54% of those without a screening test, 420/783, x
2=155.21,
p,0.01) and HSV-2 antibodies (85% (285/337) vs. 67% (521/783)
of those without a screening test, x
2=37.96, p,0.01).
Cervical Abnormalities
At enrolment, among the 30% with a screening test result
reported, prevalence of cervical abnormalities at the most recent
test was 21% (68/325) overall (17% (n=54) LSIL and 4% (n=14)
HSIL). Results were not available for 4% (12/337) of those tested,
presumably because the sample was inadequate. In total, 38%
(123/325) of women with a screening test result reported at
enrolment had the test conducted on the same day as a positive
sample was taken or diagnosis made for at least one of: chlamydia,
gonorrhoea, syphilis, HSV-2, candida, TV or BV. Among the 68
Table 4. Factors associated with having a cervical screening test reported at study enrolment, among women diagnosed with HIV
prior to most recent pregnancy.
Proportion (n) with test
reported at enrolment Crude PR n=207
{ p-value
Adjusted PR –
multivariable model
(95% CI) n=207 p- value
Age at enrolment
16–23 years 27% (12/44) 1.00
24–26 years 39% (24/62) 1.22 (0.62,2.41) 0.56
27–30 years 51% (56/110) 1.77 (0.98,3.21) 0.06
$31 years 49% (44/89) 1.93 (1.06,3.50) 0.03
Marital status
Married 55% (99/180) 1.00 1.00
Cohabiting 30% (24/80) 0.41 (0.23,0.73) ,0.01 0.58 (0.32,1.03) 0.06
Single/widowed/divorced 27% (12/44) 0.55 (0.31,0.97) 0.04 0.74 (0.42,1.31) 0.30
Age at leaving full-time education
{
$19 years 50% (60/121) 1.00 1.00
17–18 years 46% (21/46) 0.94 (0.65,1.35) 0.75 0.79 (0.56,1.13) 0.20
#16 years 36% (17/47) 0.73 (0.48,1.11) 0.15 0.66 (0.44,1.01) 0.05
Self-reported affordability of contraception
Can afford 51% (114/223) 1.00 1.00
Can’t afford 25% (19/75) 0.43 (0.25,0.74) ,0.01 0.79 (0.44,1.43) 0.44
HIV status disclosure to family or friends
Yes 51% (95/188) 1.00
No 35% (41/118) 0.61 (0.42,0.89) 0.01
WHO stage
1–2 41% (82/202) 1.00
3–4 53% (54/101) 1.32 (0.99,1.77) 0.06
Year of enrolment
2007/08 38% (36/95) 1.00 1.00
2009 45% (44/98) 1.08 (0.72,1.60) 0.72 0.85 (0.58,1.24) 0.39
2010/11 50% (56/112) 1.33 (0.91,1.93) 0.14 0.91 (0.61,1.36) 0.66
Centre of enrolment
Odessa 48% (49/102) 1.00 1.00
Kiev 56% (78/139) 1.27 (0.87,1.85) 0.22 1.11 (0.73,1.69) 0.63
Donetsk 14% (9/65) 0.39 (0.19,0.79) 0.01 0.38 (0.18,0.80) 0.01
{Limited to the 207 women included in the multivariable model.
{Significant on adjusting for year and centre (LRT p=0.01) and thus included in the multivariable model, as specified in the methods.
doi:10.1371/journal.pone.0034706.t004
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cervical abnormalities was 31% (21/68).
In crude analyses, women with BV infection were more likely to
have a diagnosis of LSIL or HSIL, as were those with two or more
previous pregnancies and those who were HSV-2 seropositive
(Table 5). No other factors were significantly associated with
abnormal findings. In the multivariable model, HSV-2 seropos-
itivity was associated with an 83% increased risk of an abnormal
finding and BV diagnosed antenatally or postnatally with over a
three-fold increased risk (Table 5).
Discussion
At enrolment in this postnatal cohort, only 30% of women had
a cervical screening test reported as part of HIV care, a third of
whom had been screened more than a year previously. Women
diagnosed with HIV prior to rather than during their most recent
pregnancy, and therefore with more opportunity to receive HIV
care, were more likely to have a cervical screening test reported at
enrolment, as were those with more previous pregnancies. A fifth
of those screened had a finding of LSIL or HSIL.
In this study, we could only assess the coverage of cervical
screening carried out as part of HIV care; women may have
accessed screening through contraceptive, sexual health or other
services. Screening is recommended six-monthly for the general
population, but it is unclear whether this policy is followed in
practice - in the 2003 World Health Survey 66% of 1361 women
reported being screened in the last three years [22], but there were
no data on screening frequency, or laboratory or clinical data, with
which to validate self-reports. In addition to more regular
screening, HIV-positive women may also benefit from more
intensive follow-up following a mild abnormal smear, a lower
threshold for referral to colposcopy (especially if severely
immunosuppressed) and more intensive surveillance immediately
following HIV diagnosis compared with the standard of care
[17,18]. However, this can only be offered if the healthcare
Table 5. Factors associated with an abnormal finding (LSIL or HSIL) on cervical screening, among women with a test reported at
study enrolment.
Proportion (n) with
abnormal result
Crude PR (95% CI)
n=213
{ p-value
Adjusted PR
{
(95% CI) n=213 p-value
Age at enrolment
16–23 years 23% (15/65) 1.00 1.00
24–26 years 23% (18/77) 1.60 (0.55–4.68) 0.39 1.52 (0.57–4.04) 0.41
27–30 years 24% (21/89) 1.97 (0.72–5.40) 0.19 1.72 (0.69–4.31) 0.24
$31 years 20% (14/69) 1.81 (0.65–5.05) 0.26 1.42 (0.56–3.60) 0.46
Previous pregnancies at enrolment
$2 26% (51/195) 1.00 1.00
1 15% (14/92) 0.44 (0.21–0.93) 0.03 0.56 (0.26–1.22) 0.15
CD4 count
.350 cells/mm
3 22% (50/228) 1.00 1.00
201–350 cells/mm
3 21% (11/53) 1.21 (0.65–2.27) 0.55 1.36 (0.74–2.49) 0.33
#200 cells/mm
3 25% (5/20) 1.57 (0.65–3.77) 0.31 2.07 (0.93–4.57) 0.07
Currently smoking
No 25% (38/151) 1.00 1.00
Yes 19% (33/171) 0.99 (0.59–1.67) 0.98 0.78 (0.49–1.26) 0.31
Oral contraceptive use postnatally (any)
No 22% (61/279) 1.00 1.00
Yes 24% (11/46) 0.94 (0.46–1.93) 0.86 0.95 (0.48–1.88) 0.88
HSV-2
No 18% (22/125) 1.00 1.00
Yes 27% (40/150) 1.73 (1.00–3.00) 0.05 1.83 (1.07–3.11) 0.03
Chlamydia
No 20% (41/205) 1.00 1.00
Yes 25% (17/68) 1.32 (0.75–2.32) 0.33 0.79 (0.46–1.36) 0.40
Bacterial vaginosis
No 17% (40/236) 1.00 1.00
Yes 39% (25/64) 3.36 (2.07–5.45) ,0.01 3.49 (2.11–5.76) ,0.01
Trichonomas vaginalis
No 19% (52/269) 1.00
Yes 44% (8/18) 1.80 (0.76–4.24) 0.18
{Limited to 213 women included in the multivariable model.
{Adjusted a priori for age, previous pregnancies, CD4 count, current smoking, oral contraceptive use, HSV-2 and chlamydia and additionally for BV.
doi:10.1371/journal.pone.0034706.t005
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as HIV-positive during their most recent pregnancy, only a
quarter had been screened as part of HIV care by enrolment
despite most having returned to the HIV/AIDS Centre at .12
weeks postpartum. As there is no policy for referral of newly
diagnosed women to other services, it is likely that many did not
receive any cervical screening in the year following HIV diagnosis.
Even among the fifth of women with follow-up, coverage of
cervical screening among those with no test reported at enrolment
was only 39%.
The 30% of women with screening test results available in this
study were a selected group whose characteristics (e.g. higher
prevalence of BV) may mean findings are not generalisable to the
cohort as a whole. Nevertheless, the 21% prevalence of abnormal
findings on cytologic screening was comparable to the 23%
prevalence of LSIL/HISL among 285 HIV-positive women
recruited from a patient programme in Brooklyn from 1990–93
[32], and 27% prevalence of abnormalities reported among 1134
HIV-positive women enrolled at the European sites of a multi-site
cohort study [33]. A study of 200 HIV-positive women attending
mother-child health clinics in Zimbabwe, a country with postnatal
opportunistic testing but no national screening policy, found a
prevalence of cervical dyskaryosis of 30% [34]. In another study,
prevalence of LSIL/HSIL among 400 HIV-positive women in
South Africa was found to be 48% [33]. In the Women’s
Interagency HIV Study, a large representative US study of HIV-
positive women, the prevalence of LSIL/HSIL was lower at 15%,
possibly because all women participated in six-monthly screening
[35]. The role of ART in prevention of HPV-related cervical
lesions or promotion of their regression is unclear [36–40]. With
further roll-out of ART (currently available to only around half of
adults with advanced HIV disease in Ukraine [2]) and decline in
deaths due to other AIDS-defining diseases, the proportion of
deaths attributable to cervical cancer may increase [41],
particularly as the HIV-positive population ages.
There was a high prevalence of a number of co-factors
implicated in the aetiology of cervical cancer in this cohort,
including smoking, chlamydia and HSV-2 infections [31]. In
adjusted analyses, HSV-2 seropositivity was associated with an
80% increased risk of LSIL/HSIL and BV with over a three-fold
increased risk. These associations could have been due to selective
screening of women at high risk for both HPV infection and
infection with HSV-2 or BV (e.g. women with multiple sexual
partners). However, co-infections to HPV may increase the risk of
cervical cancer due to the effect of reactive oxidative metabolites
generated by inflammatory processes local to the cervix [42], or by
acting as cofactors [42]. A pooled analysis of seven studies found
an increased risk of invasive cervical cancer associated with HSV-2
seropositivity independent of HPV infection and sexual risk
behaviours [43]. Evidence of an association between BV and HPV
acquisition/persistence or cervical abnormalities is less well
established [44–49], but a recent meta-analysis of twelve studies
(only three of which independently showed an association between
BV and cervical HPV infection) demonstrated a significantly
increased risk of cervical HPV infection among women with BV
(combined OR 1.43, 95% CI 1.11–1.84) [50]. Two studies
including HIV-positive women (one of which was included in the
meta-analysis) showed an association between BV and both
incident and prevalent cervical HPV infection, independent of
sexual risk factors [51,52]. Given the prevalence of BV in this
cohort (17%), and the associated risk of other adverse effects
(including preterm delivery [53] and STI acquisition [54]), regular
screening for BV with prompt treatment where indicated should
be a priority.
Women in poorer socioeconomic groups are less likely to be
screened for cervical abnormalities in the US [55], and in Ukraine,
where World Household Survey data showed coverage with three-
yearly screening of 87% in the top and 68% in the bottom wealth
quintiles [23]. HIV-positive women may be socially disadvantaged
due to their poor health, discriminatory employment practices and
coexisting behaviours (e.g. IDU). In our study, a fifth reported
being unable to afford contraception and a third had not disclosed
their HIV status to a parent, family member or friend, indicating
both economic and social marginalisation. Among those diagnosed
prior to conception, women with fewest years of education were
least likely to have been screened. An organised screening
programme could improve awareness and uptake among the
most marginalised women. At an HIV clinic in the United
Kingdom, a higher uptake of cervical screening was found among
women on HAART compared with those not yet on treatment,
probably due to their on-going engagement with HIV care [56].
Regular invitations to attend the HIV/AIDS Centre for screening
could help prevent postpartum loss to follow-up among HIV-
positive women not on ART. As national policy, organised
screening programmes delivered as part of HIV care could also
lessen the regional disparities in screening coverage.
In Eastern Europe 70% of cervical cancer cases are attributed to
vaccine-preventable HPV types 16 and 18 [22,57], but HPV
vaccination programmes have yet to be introduced in Ukraine
[22]. The safety and efficacy of HPV vaccination in immune-
compromised populations have not yet been established [37].
Although an important future intervention, HPV vaccination will
not obviate the need for an organised cervical screening
programme in Ukraine.
Limitations
Lack of data on cervical HPV infection or sexual risk behaviours
precluded more detailed exploration of the association between
BV and LSIL/HSIL. False positives or negatives cannot be ruled
out, particularly as a quarter of the samples were taken in
pregnancy, 10% at ,12 weeks postpartum and 38% on the same
day as a positive sample for a genital infection [20]. We are not
able to comment on sensitivity and specificity of cytologic
screening in this population, as colposcopy and histology takes
place at referral hospitals and data are not routinely shared with
the HIV/AIDS Centre. Because women with a screening test had
a higher prevalence of BV than those without, the observed
prevalence of cervical abnormalities in this study could be an
overestimate. Furthermore, since cervical screening test results
were only available for 30% of women, selection bias in the
association between BV and cervical abnormalities (e.g. due to
sexual risk-taking behaviour) cannot be ruled out. Local
differences exist in provision of cervical screening services both
within and outside of HIV care, and our results may therefore not
be generalizable to other areas in Ukraine. Finally, coverage of
cervical screening as part of HIV care may be higher in this cohort
than in the wider population of HIV-positive women in Ukraine,
as all women in the cohort were in contact with HIV healthcare
services.
In conclusion, cervical screening coverage of this high risk
population as part of HIV care is low. An organised programme
where women are invited to attend the HIV/AIDS Centre for
cervical screening could increase coverage, particularly among
marginalised women. BV testing and treatment could potentially
reduce vulnerability to cervical abnormalities.
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